[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cdkn2a-wt-allele":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CDKN2A wt Allele",42,38,[8,16,22,28,34,40,46,53,59,65,71,77,83,89,95,101,108,114,120,126,131,137,143,149,155,161,167,173,179,185,192,198,204,210,216,222,228,234,240,247,253,259],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07178301","Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial",[12],"Phase 2","RECRUITING","2026-08-26T02:15:58.452248Z","2026-07-19T19:36:05.065224Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05317000","5-Azacytidine and\u002For Nivolumab in Resectable HPV-Associated HNSCC",[12],"2026-08-26T02:15:18.897219Z","2026-06-17T02:29:29.995073Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07513389","Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)",[12],"2026-08-26T02:17:45.190188Z","2026-05-29T15:36:40.194242Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06984861","A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer",[12],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:29.643338Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT05268614","Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma",[12],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.512737Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT06554158","De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers",[],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.477332Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":51,"content_modified":52},"NCT06385080","A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer",[50],"Phase 1\u002FPhase 2","2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.372476Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06088381","Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)",[12],"2026-08-26T02:18:26.932189Z","2026-05-05T02:43:29.296327Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT03215719","Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:29.074089Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT04988074","Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w\u002FHPV H&N Ca",[12],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:28.875169Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT05419089","The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)",[12],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.852988Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT06323460","Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer",[12],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:28.846466Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT05541016","De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.485078Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT05894083","A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.218746Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT05799144","pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w\u002FAdvanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer",[12],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:28.217841Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":106,"content_modified":107},"NCT06563479","A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer",[105],"Phase 3","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.989005Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07044635","Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.806024Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT03875716","Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma",[],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:27.669935Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05962242","HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.631667Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":63,"content_modified":130},"NCT07172256","CUE-101with Pembrolizumab for LA-HPV+HNSCCs",[12],"2026-05-05T02:43:27.601527Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT06256588","A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma",[105],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:27.479125Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":141,"content_modified":142},"NCT05388773","Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer",[12],"2026-08-26T02:17:53.433613Z","2026-05-05T02:43:27.421473Z",{"nct_id":144,"title":145,"phases":146,"status":13,"updated_at":147,"content_modified":148},"NCT06902623","Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy",[],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:27.405933Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT06309225","Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly",[],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.403976Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT05800574","Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer",[12],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.274627Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT07290621","Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:26.936724Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT04852328","Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma",[12],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.932385Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT06445114","Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer",[12],"2026-08-26T02:17:27.435233Z","2026-04-29T02:57:57.120187Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT07497607","Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma",[12],"2026-08-26T02:15:47.754948Z","2026-04-29T02:57:57.100938Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":190,"content_modified":191},"NCT05172245","Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer",[189],"Phase 1","2026-08-26T02:17:41.695983Z","2026-07-19T19:36:05.120891Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT07195734","Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer",[12],"2026-08-26T02:18:11.042248Z","2026-07-05T05:32:16.659005Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT07156227","Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma",[189],"2026-08-26T02:17:44.240289Z","2026-06-04T01:30:07.902043Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT05013216","Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",[189],"2026-08-26T02:16:23.080181Z","2026-05-05T02:43:26.738998Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT04564989","Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC",[],"2026-08-26T02:18:57.189473Z","2026-05-13T02:55:06.254087Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT06356272","Oropharynx (OPX) Biomarker Trial",[],"2026-08-26T02:15:10.362237Z","2026-05-13T02:55:06.483201Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT04857528","Detecting HPV DNA in Anal and Cervical Cancers",[],"2026-08-26T02:16:24.970704Z","2026-05-13T02:55:06.273834Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT06183268","Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy",[],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.189047Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT06532279","Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer",[12],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:28.872744Z",{"nct_id":241,"title":242,"phases":243,"status":244,"updated_at":245,"content_modified":246},"NCT07270120","Senolytics for Secondary Progressive MS",[189],"NOT_YET_RECRUITING","2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.843913Z",{"nct_id":248,"title":249,"phases":250,"status":244,"updated_at":251,"content_modified":252},"NCT07346196","A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck",[12],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.494114Z",{"nct_id":254,"title":255,"phases":256,"status":244,"updated_at":257,"content_modified":258},"NCT07428148","Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma",[50],"2026-08-26T02:19:05.360997Z","2026-04-29T02:57:57.115905Z",{"nct_id":260,"title":261,"phases":262,"status":263,"updated_at":264,"content_modified":265},"NCT04444869","Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer",[12],"UNKNOWN","2026-08-03T01:56:19.375288Z","2026-05-05T02:43:27.629541Z"]